The latest price target for Arcus Biosciences (NYSE:RCUS) was reported by HC Wainwright & Co. on December 12, 2025. The analyst firm set a price target for $32.00 expecting RCUS to rise to within 12 months (a possible 48.70% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Arcus Biosciences (NYSE:RCUS) was provided by HC Wainwright & Co., and Arcus Biosciences maintained their buy rating.

The last upgrade for Arcus Biosciences Inc happened on February 26, 2025 when HC Wainwright & Co. raised their price target to $24. HC Wainwright & Co. previously had a neutral for Arcus Biosciences Inc.

There is no last downgrade for Arcus Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcus Biosciences was filed on December 12, 2025 so you should expect the next rating to be made available sometime around December 12, 2026.

While ratings are subjective and will change, the latest Arcus Biosciences (RCUS) rating was a maintained with a price target of $28.00 to $32.00. The current price Arcus Biosciences (RCUS) is trading at is $21.52, which is out of the analyst’s predicted range.